

Leerink Partners Coverage List

Updated on: 11/10/2023

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	P/E			Shares Outstanding (MM)	Market Cap (\$MM)	
										2022E	2023E	2024E			
1	2seventy bio, Inc.	TSVT	Market Perform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	2.22	(6.82)	(4.59)	(1.68)	NA	NA	NA	50.5	112
2	4D Molecular Therapeutics, Inc.	FDMT	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	10.50	(3.32)	(2.19)	(3.37)	NA	NA	NA	42.1	442
3	908 Devices Inc.	MASS	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	5.03	(1.07)	(1.14)	(1.08)	NA	NA	NA	32.4	163
4	89bio, Inc.	ETNB	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	7.36	(2.93)	(2.00)	(2.51)	NA	NA	NA	75.5	556
5	Abbisko Therapeutics Co., Ltd.*	2256 HK	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	HKD 3.61	¥-0.80	¥-0.82	¥-1.10	NA	NA	NA	702.2	HKD 2,534.94
6	AbbVie Inc. @*	ABBV	Market Perform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	136.81	13.77	11.24	11.22	9.9	12.2	12.2	1,765.5	241,543
7	Abcam plc#^	ABCM	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Dec	23.07	£0.25	£0.38	£0.36	92.3	60.7	64.1	232.7	5,368
8	AbCellera Biologics Inc.	ABCL	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	3.97	0.50	(0.45)	(0.44)	7.9	NA	NA	290.2	1,151
9	AC Immune SA#--	ACIU	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	2.92	(CHF 0.85)	(CHF 0.25)	(CHF 0.55)	NA	NA	NA	83.6	244
10	Acadia Healthcare Company, Inc.*#	ACHC	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	72.52	3.16	3.46	3.86	22.9	21.0	18.8	92.2	6,687
11	ACADIA Pharmaceuticals Inc.#--	ACAD	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	22.00	(1.34)	(0.35)	1.60	NA	NA	13.8	164.2	3,612
12	Aclaris Therapeutics, Inc.	ACRS	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	4.78	(1.33)	(1.70)	(1.77)	NA	NA	NA	70.8	339
13	Acorda Therapeutics, Inc.*	ACOR	Suspended Coverage		Biopharma / Infectious Disease, Endocrine & Healthcare Providers and Managed Care	Dec	9.72	NA	NA	NA	NA	NA	NA	46.3	450
14	AdaptHealth Corp.^	AHCO	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	6.84	0.38	0.42	0.49	18.0	16.3	14.0	136.4	933
15	Adaptimmune Therapeutics plc#	ADAP	Market Perform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	0.51	(0.17)	(0.09)	(0.07)	NA	NA	NA	227.1	115
16	Affimed N.V.#	AFMD	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	0.33	(€ 0.66)	(€ 0.73)	(€ 0.59)	NA	NA	NA	149.3	49
17	Agilent Technologies, Inc.**	A	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Oct	106.26	5.22	5.40	5.69	20.4	19.7	18.7	292.6	31,090
18	agilon health, inc.	AGL	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	11.37	(0.26)	(0.17)	0.13	NA	NA	87.5	410.3	4,665
19	Agios Pharmaceuticals, Inc.	AGIO	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	21.20	(4.23)	(6.29)	(6.75)	NA	NA	NA	55.9	1,185
20	AirSculpt Technologies, Inc.*#	AIRS	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	5.84	(0.25)	0.03	0.23	NA	NA	25.4	56.8	332
21	Aldeyra Therapeutics, Inc.	ALDX	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	2.23	(1.06)	(0.90)	(1.85)	NA	NA	NA	58.8	131
22	Alignment Healthcare, Inc.	ALHC	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	5.78	(0.82)	(0.78)	(0.53)	NA	NA	NA	189.1	1,093
23	Aligos Therapeutics, Inc.	ALGS	Market Perform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Cardiovascular Disorders	Dec	0.69	(2.25)	(1.51)	(0.45)	NA	NA	NA	71.8	50
24	Alkermes plc<	ALKS	Market Perform	Marc Goodman	Biopharma / Neuroscience	Dec	23.93	0.34	1.70	2.30	70.4	14.1	10.4	166.9	3,993
25	Allakos Inc.	ALLK	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.77	(5.05)	(1.83)	(1.87)	NA	NA	NA	86.9	154
26	AlloVir, Inc.	ALVR	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	1.35	(2.20)	(1.64)	(2.07)	NA	NA	NA	114.1	154
27	Alnylam Pharmaceuticals, Inc. @*	ALNY	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	159.53	(9.30)	(3.88)	(2.43)	NA	NA	NA	131.3	20,946
28	Alpine Immune Sciences, Inc.	ALPN	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	12.00	(1.73)	(1.17)	(1.73)	NA	NA	NA	58.0	696
29	Amarin Corporation plc<	AMRN	Market Perform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Healthcare Providers and Managed Care	Dec	0.70	(0.12)	0.00	(0.15)	NA	NA	NA	387.9	272
30	Amedisys, Inc.^	AMED	Market Perform	Whit Mayo	Healthcare Providers and Managed Care	Dec	92.96	5.00	4.11	3.97	18.6	22.6	23.4	32.6	3,034
31	Amgen Inc. @*	AMGN	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	263.70	17.68	18.51	21.23	14.9	14.2	12.4	535.2	141,126
32	Amicus Therapeutics, Inc.	FOLD	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	9.99	(0.82)	(0.42)	(0.07)	NA	NA	NA	293.2	2,930
33	Amylyx Pharmaceuticals, Inc.	AMLX	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	12.51	(3.39)	0.85	1.35	NA	14.7	9.3	67.4	843

Leerink Partners Coverage List

Updated on: 11/10/2023

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	P/E			Shares Outstanding (MM)	Market Cap (\$MM)
										2022E	2023E	2024E		
34 AN2 Therapeutics, Inc.	ANTX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	15.00	(2.79)	(2.94)	(3.29)	NA	NA	NA	29.7	446
35 Applied Molecular Transport Inc.#	AMTI	Market Perform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	0.17	(3.25)	(0.95)	(0.76)	NA	NA	NA	39.9	7
36 Aptinyx Inc.	APTX	Market Perform	Marc Goodman	Biopharma / Neuroscience	Dec	0.06	(1.00) E	(0.40)	(0.10)	NA	NA	NA	67.7	4
37 Arbutus Biopharma Corporation	ABUS	Suspended Coverage		Biopharma / Infectious Disease, Endocrine & Biopharma / Immuno-	Dec	1.77	NA	NA	NA	NA	NA	NA	167.7	296
38 Arcellx, Inc.	ACLX	Outperform	Daina M. Graybosch, Ph.D.	Oncology Biopharma / Immuno-	Dec	43.93	(4.56)	(1.90)	(1.60)	NA	NA	NA	48.4	2,124
39 Arcus Biosciences, Inc.	RCUS	Outperform	Daina M. Graybosch, Ph.D.	Oncology Biopharma / Immunology	Dec	13.27	(3.71)	(4.31)	(4.24)	NA	NA	NA	74.9	993
40 argenx SE#	ARGX	Outperform	Thomas J. Smith	& Metabolism Biopharma / Genetic	Dec	483.90	(13.05)	(4.52)	(2.33)	NA	NA	NA	59.1	28,588
41 Arrowhead Pharmaceuticals, Inc.	ARWR	Market Perform	Mani Foroohar, M.D.	Medicine Biopharma / Infectious	Sep	26.47	(1.67)	(0.79)	(0.45)	NA	NA	NA	107.2	2,837
42 ARS Pharmaceuticals, Inc.	SPRY	Market Perform	Roanna Ruiz, Ph.D.	Disease, Endocrine & Biopharma / Targeted	Dec	3.63	(0.87)	(0.60)	(0.60)	NA	NA	NA	95.6	347
43 Arvinas, Inc.@*	ARVN	Outperform	Christopher Liu, Pharm.D.	Oncology Biopharma / Rare	Dec	14.24	(5.31)	(3.89)	(6.43)	NA	NA	NA	94.9	1,351
44 Ascendis Pharma A/S	ASND	Outperform	Joseph P. Schwartz	Diseases Biopharma / Infectious	Dec	89.29	(€ 10.40)	(€ 9.87)	(€ 11.98)	NA	NA	NA	57.2	5,103
45 Assembly Biosciences, Inc.	ASMB	Suspended Coverage		Disease, Endocrine & Biopharma / Targeted	Dec	0.74	(2.20)	NA	NA	NA	NA	NA	65.7	49
46 AstraZeneca PLC^#	AZN	Outperform	Andrew Berens, M.D.	Oncology Biopharma / Infectious	Dec	62.42	3.33	3.60	4.17	18.7	17.3	15.0	1,550.0	96,751
47 Atea Pharmaceuticals, Inc.	AVIR	Market Perform	Roanna Ruiz, Ph.D.	Disease, Endocrine & Biopharma / Targeted	Dec	2.93	(1.39)	(1.61)	(2.80)	NA	NA	NA	83.4	244
48 Aura Biosciences, Inc.~#	AURA	Outperform	Andrew Berens, M.D.	Oncology Biopharma / Rare	Dec	7.23	(1.96)	(1.93)	(1.96)	NA	NA	NA	49.2	356
49 Aurinia Pharmaceuticals Inc.	AUPH	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	7.69	(0.76)	(0.51)	(0.40)	NA	NA	NA	143.6	1,104
50 Avadel Pharmaceuticals plc	AVDL	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	10.47	(2.29)	(1.95)	(0.10)	NA	NA	NA	89.8	940
51 Avidity Biosciences, Inc.	RNA	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	5.25	(3.34)	(3.00)	(3.87)	NA	NA	NA	74.1	389
52 Axogen, Inc.~^~	AXGN	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	4.92	(0.30)	(0.12)	0.07	NA	NA	70.3	43.0	212
53 Axonics, Inc.	AXNX	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	50.11	(1.28)	(0.19)	0.26	NA	NA	NA	50.7	2,539
54 Axsome Therapeutics, Inc.#~~	AXSM	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	57.01	(4.57)	(4.40)	(3.95)	NA	NA	NA	47.3	2,697
55 Beam Therapeutics, Inc.	BEAM	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	21.97	(4.13)	(2.10)	(3.73)	NA	NA	NA	81.5	1,791
56 BeiGene, Ltd.~+	BGNE	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	195.09	(19.43)	(5.64)	(9.29)	NA	NA	NA	104.7	20,426
57 Belite Bio, Inc#~~	BLTE	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	38.62	(0.63)	(1.40)	0.30	NA	NA	NA	25.2	974
58 Bicycle Therapeutics plc	BCYC	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	13.27	(3.80)	(4.96)	(3.75)	NA	NA	NA	37.7	500
59 Biogen Inc.@*	BIIB	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	221.56	17.69	14.75	16.75	12.5	15.0	13.2	144.9	32,104
60 Biohaven Ltd.~^~	BHVN	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	28.69	(12.75)	(5.00)	(4.35)	NA	NA	NA	80.1	2,297
61 BioMarin Pharmaceutical Inc.	BMRN	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	83.49	0.75	1.03	1.21	NA	81.1	69.0	188.4	15,727
62 BioNTech SE#	BNTX	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	98.94	37.77	5.18	2.32	2.6	19.1	42.6	243.0	24,043
63 Bio-Rad Laboratories, Inc.**	BIO	Suspended Coverage		Life Science Tools and Diagnostics	Dec	299.47	NA	NA	NA	NA	NA	NA	29.1	8,728
64 Bio-Techne Corporation**	TECH	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Jun	56.19	1.97	1.99	1.79	28.5	28.2	31.4	158.2	8,886
65 bluebird bio, Inc.@*	BLUE	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	2.91	(3.73)	(1.86)	(1.95)	NA	NA	NA	109.3	318
66 Blueprint Medicines Corporation	BPMC	Underperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	57.88	(9.35)	(8.71)	(5.18)	NA	NA	NA	60.8	3,519
67 Bolt Biotherapeutics, Inc.	BOLT	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	0.98	(2.39)	(1.65)	(1.70)	NA	NA	NA	38.0	37
68 Bii Biosciences Limited#	2137 HK	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Cardiovascular Disorders	Dec	HKD 2.96	¥-0.67	¥-1.32	¥-1.15	NA	NA	NA	729.1 HKD	2,158.15

Leerink Partners Coverage List

Updated on: 11/10/2023

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	P/E			Shares Outstanding	Market Cap	
										2022E	2023E	2024E	(MM)	(\$MM)	
69	BridgeBio Pharma, Inc.	BBIO	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	26.55	(3.26)	(3.44)	(3.09)	NA	NA	NA	174.0	4,619
70	Bristol-Myers Squibb Company	BMJ	Market Perform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	49.67	7.70	7.56	7.61	6.5	6.6	6.5	2,034.8	101,056
71	Bruker Corporation**	BRKR	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	56.92	2.33	2.53	2.83	24.4	22.5	20.1	146.9	8,359
72	C4 Therapeutics, Inc. @*	CCCC	Outperform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	1.67	(2.62)	(2.56)	(2.95)	NA	NA	NA	49.3	82
73	CareDx, Inc.	CDNA	Suspended Coverage		Life Science Tools and Diagnostics	Dec	7.04	NA	NA	NA	NA	NA	NA	54.1	381
74	Caribou Biosciences, Inc.	CRBU	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	3.78	(1.66)	(1.48)	(1.62)	NA	NA	NA	88.4	334
75	Castle Biosciences, Inc.	CSTL	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	16.47	(3.28)	(2.86)	(2.60)	NA	NA	NA	26.9	443
76	Celldex Therapeutics, Inc.	CLDX	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	26.96	(2.40)	(2.89)	(2.91)	NA	NA	NA	47.3	1,274
77	Centessa Pharmaceuticals plc	CNTA	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	6.33	(2.31)	(1.63)	(1.55)	NA	NA	NA	97.4	617
78	Century Therapeutics, Inc.	IPSC	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	1.33	(2.27)	(2.17)	(1.95)	NA	NA	NA	59.8	79
79	Cidara Therapeutics, Inc.	CDTX	Suspended Coverage		Oncology / Infectious Disease, Endocrine & Healthcare Providers and	Dec	0.80	NA	NA	NA	NA	NA	NA	90.4	72
80	The Cigna Group~^	CI	Market Perform	Whit Mayo	Managed Care Healthcare Providers and	Dec	288.38	23.26	24.80	28.20	12.4	11.6	10.2	292.6	84,385
81	Clover Health Investments, Corp.	CLOV	Market Perform	Whit Mayo	Managed Care Healthcare Providers and	Dec	0.89	(0.71)	(0.48)	(0.10)	NA	NA	NA	480.8	428
82	Cogent Biosciences, Inc.	COGT	Outperform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	6.80	(2.39)	(2.46)	(2.63)	NA	NA	NA	86.1	586
83	Compass Therapeutics, Inc.	CMPX	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	1.56	(0.37)	(0.31)	(0.54)	NA	NA	NA	127.5	199
84	Compugen Ltd.	CGEN	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	0.56	(0.39)	(0.16)	(0.62)	NA	NA	NA	88.3	49
85	Connect Biopharma Holdings Limited#	CNTB	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.74	(CNY 14.48)	(CNY 8.11)	(CNY 6.95)	NA	NA	NA	55.1	96
86	Corcept Therapeutics Incorporated	CORT	Market Perform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Biopharma / Rare	Dec	24.95	0.95	1.01	0.75	26.3	24.7	33.3	103.1	2,572
87	Crinetics Pharmaceuticals, Inc.	CRNX	Outperform	Joseph P. Schwartz	Diseases Biopharma / Genetic Medicine	Dec	26.24	(3.15)	(3.75)	(4.15)	NA	NA	NA	66.8	1,753
88	CRISPR Therapeutics AG	CRSP	Outperform	Mani Foroohar, M.D.	Life Science Tools and Diagnostics	Dec	50.41	(8.36)	(4.48)	(6.53)	NA	NA	NA	79.4	4,004
89	Cryoport, Inc.	CYRX	Market Perform	Puneet Souda	Biopharma / Targeted Oncology	Dec	11.04	(0.93)	(1.09)	(1.13)	NA	NA	NA	48.9	540
90	Cullinan Oncology, Inc.	CGEM	Outperform	Andrew Berens, M.D.	Biopharma / Genetic Medicine	Dec	9.42	2.38	(4.14)	(4.39)	4.0	NA	NA	42.8	403
91	CureVac N.V.	CVAC	Outperform	Mani Foroohar, M.D.	Biopharma / Immunology & Metabolism	Dec	5.34	(1.32)	(0.69)	(0.42)	NA	NA	NA	223.9	1,196
92	CymaBay Therapeutics, Inc.*##	CBAY	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	16.34	(1.21)	(0.96)	(1.55)	NA	NA	NA	113.4	1,853
93	Cytokinetics, Incorporated	CYTK	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Cardiovascular Disorders	Dec	32.87	(4.25)	(4.55)	(3.95)	NA	NA	NA	98.1	3,223
94	Danaher Corporation^	DHR	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	194.12	10.95	8.29	7.27	17.7	23.4	26.7	738.9	143,441
95	Deciphera Pharmaceuticals, Inc.	DCPH	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	11.26	(2.37)	(2.28)	(2.42)	NA	NA	NA	80.1	902
96	Denali Therapeutics Inc.	DNLI	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	16.56	(2.60)	(1.10)	(3.70)	NA	NA	NA	138.2	2,289
97	Design Therapeutics, Inc.	DSGN	Market Perform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	2.00	(1.14)	(1.66)	(2.58)	NA	NA	NA	56.0	112
98	DexCom, Inc. @*	DXCM	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	92.77	0.82	1.09	1.76	NA	85.1	52.7	407.2	37,774
99	Disc Medicine, Inc.	IRON	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	47.86	(45.05)	(3.11)	(3.91)	NA	NA	NA	22.9	1,095
100	Edgewise Therapeutics, Inc.	EWTX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	5.19	(1.26)	(1.60)	(2.72)	NA	NA	NA	63.5	329
101	Editas Medicine, Inc.	EDIT	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	7.53	(3.21)	(2.15)	(2.02)	NA	NA	NA	81.7	615
102	Edwards Lifesciences Corporation~^~	EW	Market Perform	Mike Kratky, CFA	Medical Devices and Technology	Dec	64.12	2.48	2.50	2.81	25.9	25.6	22.8	606.5	38,889
103	Eledon Pharmaceuticals, Inc.	ELDN	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.15	(6.16)	(1.73)	(1.02)	NA	NA	NA	30.0	34

Source: Leerink Partners LLC, FactSet, and company data

Leerink Partners Coverage List

Updated on: 11/10/2023

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	P/E			Shares Outstanding	Market Cap
										2022E	2023E	2024E	(MM)	(\$MM)
104	Elevance Health, Inc.^	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	453.68	29.05	33.09	37.09	15.6	13.7	12.2	235.0	106,596
105	Elevation Oncology, Inc. @*	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	0.41	(4.09)	(1.45)	(1.07)	NA	NA	NA	42.4	17
106	Eli Lilly and Company @*	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	591.00	7.94	6.58	12.41	74.4	89.8	47.6	949.3	561,036
107	Enanta Pharmaceuticals, Inc.	Market Perform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Healthcare Providers and Managed Care	Sep	8.26	(5.91)	(7.25)	(6.90)	NA	NA	NA	21.1	174
108	Enhabit, Inc.	Underperform	Whit Mayo	Biopharma / Immunology & Metabolism	Dec	9.17	1.38	0.19	0.06	6.6	48.3	NA	50.1	459
109	Equillium, Inc. ##	Outperform	Thomas J. Smith	Tech-Enabled Healthcare Services	Dec	0.50	(1.85)	(0.42)	0.18	NA	NA	2.8	35.1	18
110	Evolut Health, Inc. ~~~	Suspended Coverage			Dec	27.47	NA	NA	NA	NA	NA	NA	115.0	3,157
111	Evolus, Inc. #~~	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	7.80	(1.33)	(1.05)	(0.70)	NA	NA	NA	57.2	446
112	EXACT Sciences Corporation^	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	59.08	(3.54)	(1.35)	(0.72)	NA	NA	NA	180.8	10,685
113	Exelixis, Inc. ~^~	Market Perform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	20.73	0.82	0.90	1.27	25.3	23.0	16.3	311.0	6,446
114	Fate Therapeutics, Inc.	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	1.95	(2.91)	(1.99)	(2.60)	NA	NA	NA	98.6	192
115	FibroGen, Inc.	Suspended Coverage		Biopharma / Immunology & Metabolism	Dec	0.36	(2.01)	NA	NA	NA	NA	NA	98.3	36
116	Fulcrum Therapeutics, Inc. #~~	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	3.33	(2.44)	(1.63)	(1.71)	NA	NA	NA	61.8	206
117	Fusion Pharmaceuticals Inc. @*	Outperform	Faisal A. Khurshid	Biopharma / Emerging Oncology	Dec	3.83	(2.00)	(1.39)	(1.21)	NA	NA	NA	72.4	277
118	Galapagos NV ##	Suspended Coverage		Biopharma / Immunology & Metabolism	Dec	36.00	NA	NA	NA	NA	NA	NA	65.9	2,372
119	Galecto, Inc.	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	0.57	(2.43)	(1.82)	(1.16)	NA	NA	NA	27.1	15
120	Genmab A/S#	Market Perform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	31.02	DKK 83.65	DKK 75.74	DKK 77.81	0.4	0.4	0.4	660.7	20,495
121	GENFIT S.A.#	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	3.23	(€ 0.48)	€ 0.41	€ 0.31	NA	7.9	10.4	49.8	161
122	Gilead Sciences, Inc. ~^~	Market Perform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	75.35	7.26	6.57	7.43	10.4	11.5	10.1	1,246.0	93,889
123	GlaxoSmithKline plc ~~#	Suspended Coverage		Biopharma / Diversified Biotechnology	Dec	£14.00	NA	NA	NA	NA	NA	NA	5,063.0	70,862
124	Gossamer Bio, Inc. @*	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	0.51	(2.71)	(1.23)	(0.99)	NA	NA	NA	225.3	115
125	Graphite Bio, Inc. ~#	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	2.31	(1.84)	(1.74)	(0.58)	NA	NA	NA	58.0	134
126	Guardant Health, Inc. **^	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	21.49	(4.28)	(3.27)	(3.07)	NA	NA	NA	118.0	2,536
127	Halozyme Therapeutics, Inc. @*	Market Perform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	36.90	2.21	2.80	3.86	16.7	13.2	9.6	132.1	4,874
128	Harpoon Therapeutics, Inc.	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	6.27	(2.04)	(3.26)	(2.27)	NA	NA	NA	4.0	25
129	HCA Healthcare, Inc. *#	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	228.17	16.88	17.98	19.04	13.5	12.7	12.0	267.7	61,072
130	HilleVax, Inc. @*	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	12.35	(5.89)	(3.35)	(3.75)	NA	NA	NA	47.2	583
131	Hologic, Inc.^	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Sep	71.17	6.01	3.96	4.01	11.8	18.0	17.7	244.9	17,433
132	HOOKIPA Pharma Inc. @*	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	0.48	(0.99)	(0.88)	(0.87)	NA	NA	NA	81.6	39
133	Humana Inc. ~#^	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	491.49	25.22	28.31	31.47	19.5	17.4	15.6	123.1	60,508
134	IDEAYA Biosciences, Inc.	Outperform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	29.07	(1.42)	(1.91)	(2.79)	NA	NA	NA	60.0	1,744

Leerink Partners Coverage List

														Updated on:	11/10/2023
Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	2022E	P/E			Shares Outstanding	Market Cap
											2023E	2024E	(MM)	(\$MM)	
135	illumina, Inc.**	ILMN	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	92.98	2.11	0.69	0.71	44.1	NA	NA	158.3	14,719
136	Immatics N.V.#	IMTX	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	9.07	€ 0.56	(€ 1.16)	(€ 0.40)	16.2	NA	NA	80.4	729
137	Immunic, Inc.	IMUX	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.05	(3.78)	(2.21)	(1.75)	NA	NA	NA	44.6	47
138	ImmunoGen, Inc.	IMGN	Market Perform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	14.54	(0.88)	0.02	0.19	NA	NA	76.5	266.3	3,870
139	Immunovant, Inc.@*	IMVT	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Mar	31.92	(1.43)	(1.71)	(1.79)	NA	NA	NA	130.4	4,163
140	Incyte Corporation	INCY	Market Perform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	51.61	1.52	2.45	4.07	34.0	21.1	12.7	224.1	11,566
141	inflaRx N.V.#	IFRX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	1.22	(0.67)	(0.70)	(0.60)	NA	NA	NA	58.9	72
142	Innate Pharma S.A.#	IPHA	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	€ 2.25	(€ 0.73)	(€ 0.48)	(€ 1.09)	NA	NA	NA	80.6	181
143	Innoviva, Inc.	INVA	Suspended Coverage		Biotechnology	Dec	13.37	NA	NA	NA	NA	NA	NA	64.1	857
144	Insmed Incorporated	INSM	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	23.51	(3.91)	(5.11)	(4.06)	NA	NA	NA	143.1	3,363
145	Inspire Medical Systems, Inc.	INSP	Market Perform	Mike Kratky, CFA	Medical Devices and Technology	Dec	125.61	(1.60)	(1.58)	(0.65)	NA	NA	NA	29.5	3,709
146	Insulet Corporation**^	PODD	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	154.15	0.07	2.13	3.34	NA	72.4	46.2	69.8	10,764
147	Intellia Therapeutics, Inc.@*	NTLA	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	23.44	(6.16)	(5.40)	(4.88)	NA	NA	NA	88.5	2,074
148	Intra-Cellular Therapies, Inc.#~	ITCI	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	53.23	(2.72)	(1.60)	(0.60)	NA	NA	NA	96.2	5,123
149	Intuitive Surgical, Inc.^	ISRG	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	273.08	4.68	5.52	6.64	58.4	49.5	41.1	352.1	96,144
150	Invitae Corporation	NVTA	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Dec	0.48	(2.20)	(1.00)	(0.95)	NA	NA	NA	286.5	137
151	Ionis Pharmaceuticals, Inc.@*	IONS	Market Perform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	46.15	(1.66)	(3.52)	(3.43)	NA	NA	NA	143.5	6,621
152	Ironwood Pharmaceuticals, Inc.	IRWD	Suspended Coverage		Specialty Pharmaceuticals	Dec	9.84	NA	NA	NA	NA	NA	NA	156.0	1,535
153	iTeos Therapeutics, Inc.	ITOS	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	9.27	2.56	(2.44)	(8.78)	3.6	NA	NA	35.8	332
154	Jazz Pharmaceuticals plc*#	JAZZ	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	118.07	13.13	18.50	20.50	9.0	6.4	5.8	63.0	7,433
155	Johnson & Johnson@*	JNJ	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	145.79	8.93	10.10	11.04	16.3	14.4	13.2	2,407.3	350,957
156	KalVista Pharmaceuticals, Inc.	KALV	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Apr	8.00	(3.36)	(3.32)	(2.76)	NA	NA	NA	34.4	275
157	Karuna Therapeutics, Inc.	KRTX	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	164.79	(8.74)	(5.45)	(9.30)	NA	NA	NA	37.7	6,217
158	Karyopharm Therapeutics Inc.	KPTI	Market Perform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	0.71	(2.02)	(1.15)	(0.96)	NA	NA	NA	114.5	81
159	Keros Therapeutics, Inc.@*	KROS	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	29.42	(4.15)	(5.28)	(6.01)	NA	NA	NA	30.0	881
160	Kinnate Biopharma Inc.	KNTE	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	1.18	(2.64)	(2.39)	(1.51)	NA	NA	NA	47.1	56
161	Kura Oncology, Inc.	KURA	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	8.57	(2.03)	(2.12)	(2.27)	NA	NA	NA	74.3	637
162	Kymera Therapeutics, Inc.	KYMR	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	14.20	(2.87)	(1.77)	(3.20)	NA	NA	NA	55.5	788
163	Landos Biopharma, Inc.	LABP	Market Perform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	3.83	(9.75)	(3.41)	(2.25)	NA	NA	NA	3.1	12
164	Lantheus Holdings, Inc.*#	LNTH	Outperform	Roanna Ruiz, Ph.D.	Medical Supplies and Devices	Dec	62.07	4.22	5.83	5.76	14.7	10.6	10.8	68.5	4,251
165	LAVA Therapeutics N.V.	LVTX	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	1.40	(€ 1.24)	(€ 0.84)	(€ 1.35)	NA	NA	NA	26.3	37
166	H. Lundbeck A/S^*	HLUNB DC	Market Perform	Marc Goodman	Biopharma / Neuroscience	Dec	DKK 35.26	DKK 3.74	DKK 4.40	DKK 5.15	9.4	8.0	6.8	995.7	DKK 35,109.83
167	MacroGenics, Inc.	MGNX	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	6.38	(1.95)	0.36	(1.31)	NA	17.7	NA	62.0	396
168	Madrigal Pharmaceuticals, Inc.*##	MDGL	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	135.85	(17.23)	(19.62)	(18.01)	NA	NA	NA	19.7	2,682

Leerink Partners Coverage List

															Updated on:	
															11/10/2023	
Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	2022E	2023E	2024E	P/E		Shares Outstanding (MM)	Market Cap (\$MM)
169	MannKind Corporation*##	MNKD	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	3.46	(0.34)	(0.07)	0.08	NA	NA	43.3	269.6	933	
170	Marinus Pharmaceuticals, Inc.#~~	MRNS	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	5.88	(0.41)	(2.55)	(2.20)	NA	NA	NA	54.6	321	
171	Merck & Co., Inc.	MRK	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	100.88	7.48	3.03	8.14	13.5	33.3	12.4	2,534.0	255,636	
172	Mereo BioPharma Group plc	MREO	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	2.10	(0.06)	(0.05)	0.05	NA	NA	42.0	28.0	59	
173	Mersana Therapeutics, Inc.	MRSN	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	1.19	(2.18)	(1.45)	(0.55)	NA	NA	NA	120.6	143	
174	Merus N.V.@*	MRUS	Outperform	Andrew Berens, M.D.	Biopharma / Immuno-Oncology	Dec	22.44	(2.92)	(2.74)	(3.86)	NA	NA	NA	57.7	1,296	
175	Mirati Therapeutics, Inc.@*	MRTX	Market Perform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	56.23	(13.18)	(10.86)	(9.25)	NA	NA	NA	70.1	3,944	
176	Mirum Pharmaceuticals, Inc.	MIRM	Outperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	28.62	(4.01)	(3.62)	1.74	NA	NA	16.4	46.6	1,334	
177	Moderna, Inc.	MRNA	Underperform	Mani Foroohar, M.D.	Biopharma / Genetic Medicine	Dec	68.97	20.10	(13.92)	(7.46)	3.4	NA	NA	381.3	26,297	
178	Molecular Partners AG#	MOLN	Market Perform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	4.46	CHF 3.72	(CHF 1.88)	(CHF 2.44)	1.2	NA	NA	36.4	162	
179	Monte Rosa Therapeutics, Inc.@*	GLUE	Market Perform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	3.09	(2.30)	(1.72)	(1.95)	NA	NA	NA	49.6	153	
180	MoonLake Immunotherapeutics AG	MLTX	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	38.12	(1.70)	(0.92)	(1.08)	NA	NA	NA	53.5	2,039	
181	Morphic Holding, Inc.	MORF	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	20.13	(1.55)	(3.48)	(4.18)	NA	NA	NA	49.7	1,001	
182	MorphoSys AG#	MOR GY	Suspended Coverage		Biopharma / Targeted Oncology	Dec	€ 29.17	(8.01)	NA	NA	NA	NA	NA	34.2	999	
183	Myriad Genetics, Inc.~	MYGN	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Dec	16.11	(0.30)	(0.31)	(0.05)	NA	NA	NA	82.2	1,324	
184	Nabriva Therapeutics plc#	NBRV	Suspended Coverage		Biopharma / Infectious Disease. Endocrine & Life Science Tools and Diagnostics	Dec	0.25	NA	NA	NA	NA	NA	NA	3.2	1	
185	NanoString Technologies, Inc.^	NSTG	Suspended Coverage		Life Science Tools and Diagnostics	Dec	1.10	NA	NA	NA	NA	NA	NA	48.1	53	
186	Natera, Inc.	NTRA	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	46.12	(5.57)	(3.92)	(3.05)	NA	NA	NA	114.6	5,285	
187	Nektar Therapeutics	NKTR	Market Perform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	0.46	(1.97)	(1.42)	(1.15)	NA	NA	NA	190.8	88	
188	NeoGenomics, Inc.	NEO	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	15.70	(0.56)	(0.16)	(0.09)	NA	NA	NA	127.5	2,001	
189	Neurocrine Biosciences, Inc.~#	NBIX	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	105.99	1.53	2.10	4.45	69.3	50.5	23.8	98.3	10,414	
190	NewAmsterdam Pharma Company N.V.#	NAMS	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease, Endocrine & Biopharma / Immuno-Oncology	Dec	9.95	(€ 0.96)	(€ 1.85)	(€ 1.15)	NA	NA	NA	82.3	819	
191	Nkarta, Inc.	NKTX	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	2.10	(2.65)	(3.07)	(3.09)	NA	NA	NA	49.1	103	
192	Novartis AG	NVS	Suspended Coverage		Pharmaceuticals/ Major Biopharma / Emerging Oncology	Dec	92.83	NA	NA	NA	NA	NA	NA	2,277.5	211,418	
193	NovoCure Limited@*	NVCR	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	11.06	(0.88)	(2.00)	(2.14)	NA	NA	NA	106.9	1,182	
194	Novo Nordisk A/S	NVO	Suspended Coverage		Pharmaceuticals/ Major Biopharma / Targeted Oncology	Dec	DKK 691.60	NA	NA	NA	NA	NA	NA	2,456.0	DKK 1,698,569.60	
195	Nurix Therapeutics, Inc.@*	NRIX	Outperform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Nov	5.13	(3.71)	(1.49)	(3.81)	NA	NA	NA	48.5	249	
196	Nuvalent, Inc.	NUVL	Market Perform	Christopher Liu, Pharm.D.	Biopharma / Targeted Oncology	Dec	56.61	(1.65)	(2.32)	(2.77)	NA	NA	NA	56.9	3,224	
197	Oculus Holding AG	OCS	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	9.80	CHF 0.00	(CHF 4.95)	(CHF 0.65)	NA	NA	NA	36.4	357	
198	Olink Holding AB@*	OLK	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Dec	24.74	(0.07)	(0.11)	(0.08)	NA	NA	NA	124.3	3,076	
199	OmniAb, Inc.	OABI	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	4.24	(0.27)	(0.54)	(0.54)	NA	NA	NA	116.2	492	
200	Opthea Limited	OPT	Outperform	Marc Goodman	Biopharma / Neuroscience	Jun	1.73	(0.26)	(0.32)	(0.21)	NA	NA	NA	82.9	143	
201	Pediatrix Medical Group, Inc.^	MD	Market Perform	Whit Mayo	Healthcare Providers and Managed Care	Dec	9.12	1.66	1.30	1.16	5.5	7.0	7.9	84.0	766	
202	PepGen Inc.	PEPG	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	4.08	(4.42)	(3.58)	(4.36)	NA	NA	NA	23.8	97	

Leerink Partners Coverage List

															Updated on:	
															11/10/2023	
Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	2022E	2023E	2024E	P/E		Shares Outstanding (MM)	Market Cap (\$MM)
203	PerkinElmer, Inc.**	PKI	Suspended Coverage	Life Science Tools and Diagnostics	Dec	82.50	NA	NA	NA	NA	NA	NA	NA	NA	123.4	10,181
204	Pfizer Inc.@*	PFE	Market Perform	David Risinger, CFA	Dec	29.12	6.58	1.62	3.34	4.4	18.0	8.7	5,646.4	164,424		
205	Pharvaris N.V.	PHVS	Outperform	Joseph P. Schwartz	Dec	16.04	(€ 2.27)	(€ 2.52)	(€ 2.57)	NA	NA	NA	40.9	655		
206	Pliant Therapeutics, Inc.	PLRX	Outperform	Thomas J. Smith	Dec	14.24	(2.94)	(2.80)	(3.34)	NA	NA	NA	59.8	852		
207	POINT Biopharma Global Inc.@*	PNT	Market Perform	Faisal A. Khurshid	Dec	13.10	1.02	(1.13)	(1.40)	12.8	NA	NA	105.8	1,386		
208	Privia Health Group, Inc.	PRVA	Outperform	Whit Mayo	Dec	22.07	(0.10)	0.22	0.31	NA	NA	71.2	118.1	2,606		
209	PROCEPT BioRobotics Corporation	PRCT	Outperform	Mike Kratky, CFA	Dec	30.11	(1.96)	(2.09)	(1.96)	NA	NA	NA	50.5	1,521		
210	Prothena Corporation plc	PRTA	Outperform	Rudy Li, Ph.D., CFA	Dec	32.84	(2.50)	(2.54)	(3.30)	NA	NA	NA	53.7	1,762		
211	PTC Therapeutics, Inc.	PTCT	Market Perform	Joseph P. Schwartz	Dec	18.46	(7.79)	(5.62)	(2.94)	NA	NA	NA	75.5	1,393		
212	PureTech Health plc#	PRTC	Outperform	Thomas J. Smith	Dec	20.33	(1.77)	(4.45)	(2.92)	NA	NA	NA	27.7	563		
213	QIAGEN N.V.**	QGEN	Suspended Coverage	Life Science Tools and Diagnostics	Dec	37.55	NA	NA	NA	NA	NA	NA	228.0	8,563		
214	Quanterix Corporation*#	QTRX	Outperform	Puneet Souda	Dec	20.08	(1.78)	(0.78)	(0.69)	NA	NA	NA	37.8	759		
215	Rain Oncology Inc.@*	RAIN	Market Perform	Faisal A. Khurshid	Dec	1.10	(2.71)	(1.47)	(0.35)	NA	NA	NA	36.4	40		
216	RAPT Therapeutics, Inc.	RAPT	Outperform	Thomas J. Smith	Dec	11.16	(2.58)	(2.93)	(3.27)	NA	NA	NA	34.4	383		
217	Recursion Pharmaceuticals, Inc.	RXRX	Market Perform	Mani Foroohar, M.D.	Dec	5.16	(1.36)	(1.71)	(1.81)	NA	NA	NA	204.0	1,052		
218	Regeneron Pharmaceuticals, Inc.@*	REGN	Outperform	David Risinger, CFA	Dec	787.40	44.98	42.71	44.26	17.5	18.4	17.8	107.1	84,353		
219	REGENXBIO Inc.@*	RGNX	Market Perform	Mani Foroohar, M.D.	Dec	17.24	(6.50)	(5.39)	(2.67)	NA	NA	NA	44.0	758		
220	Relay Therapeutics, Inc.	RLAY	Outperform	Christopher Liu, Pharm.D.	Dec	7.42	(2.59)	(2.89)	(2.59)	NA	NA	NA	123.3	915		
221	Relmada Therapeutics, Inc.#~	RLMD	Outperform	Marc Goodman	Dec	2.93	(5.30)	(3.35)	(2.60)	NA	NA	NA	30.1	88		
222	Reneo Pharmaceuticals, Inc.	RPHM	Outperform	Joseph P. Schwartz	Dec	6.09	(2.12)	(2.58)	(2.04)	NA	NA	NA	33.8	206		
223	Repligen Corporation*#	RGEN	Outperform	Puneet Souda	Dec	145.59	3.28	1.73	1.66	44.4	84.2	87.7	55.8	8,129		
224	Replimune Group, Inc.	REPL	Outperform	Jonathan Chang, Ph.D., CFA	Mar	11.24	(2.99)	(3.64)	(3.61)	NA	NA	NA	59.1	664		
225	Revolution Medicines, Inc.	RVMD	Outperform	Jonathan Chang, Ph.D., CFA	Dec	18.99	(3.08)	(3.37)	(2.76)	NA	NA	NA	109.6	2,081		
226	Rigel Pharmaceuticals, Inc.	RIGL	Suspended Coverage	Oncology / Immunology & Metabolism	Dec	0.77	NA	NA	NA	NA	NA	NA	174.4	134		
227	Rocket Pharmaceuticals, Inc.@*	RCKT	Outperform	Mani Foroohar, M.D.	Dec	18.17	(3.26)	(2.99)	0.19	NA	NA	95.6	90.2	1,638		
228	Roivant Sciences Ltd.@*	ROIV	Outperform	David Risinger, CFA	Mar	8.75	(0.85)	(1.15)	(0.91)	NA	NA	NA	791.3	6,920		
229	Sage Therapeutics, Inc.#~	SAGE	Market Perform	Marc Goodman	Dec	16.91	(8.98)	(9.75)	(4.40)	NA	NA	NA	60.0	1,014		
230	Sanofi*#	SAN FP	Outperform	David Risinger, CFA	Dec	€ 85.48	€ 8.26	€ 8.18	€ 7.85	10.3	10.4	10.9	1,264.8	€ 108,114.26		
231	Sarepta Therapeutics, Inc.	SRPT	Outperform	Joseph P. Schwartz	Dec	76.64	(8.03)	(6.23)	5.77	NA	NA	13.3	93.5	7,169		
232	scPharmaceuticals Inc.	SCPH	Outperform	Roanna Ruiz, Ph.D.	Dec	4.93	(1.30)	(1.60)	(1.40)	NA	NA	NA	35.9	177		
233	Seagen Inc.	SGEN	Market Perform	Andrew Berens, M.D.	Dec	213.75	(3.30)	(4.07)	(1.28)	NA	NA	NA	188.7	40,326		
234	Selecta Biosciences, Inc.@*	SELB	Market Perform	Joseph P. Schwartz	Dec	0.96	0.10	(0.28)	0.15	9.6	NA	6.4	155.2	149		
235	Shockwave Medical, Inc.	SWAV	Outperform	Mike Kratky, CFA	Dec	158.83	5.70	3.87	6.04	27.9	41.0	26.3	36.9	5,860		
236	Sio Gene Therapies, Inc.	SIOX	Suspended Coverage	Biopharma / Genetic	Mar	0.40	NA	NA	NA	NA	NA	NA	73.5	30		
237	Solid Biosciences Inc.	SLDB	Market Perform	Joseph P. Schwartz	Dec	2.08	(10.10)	(4.79)	(3.99)	NA	NA	NA	20.2	42		
238	Spruce Biosciences, Inc.	SPRB	Outperform	Joseph P. Schwartz	Dec	1.06	(1.96)	(1.52)	(1.64)	NA	NA	NA	40.7	43		
239	Stoke Therapeutics, Inc.	STOK	Outperform	Rudy Li, Ph.D., CFA	Dec	4.40	(2.60)	(2.50)	(2.55)	NA	NA	NA	44.7	196		
240	Structure Therapeutics Inc.	GPCR	Outperform	David Risinger, CFA	Dec	53.93	(5.51)	(0.87)	(0.84)	NA	NA	NA	41.8	2,254		

Leerink Partners Coverage List

Updated on: 11/10/2023

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	2022E	2023E	2024E	Shares Outstanding (MM)	Market Cap (\$MM)	
241	Surgery Partners, Inc.*#	SGRY	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	25.65	0.16	0.95	1.04	NA	27.0	24.7	126.5	3,245
242	Synlogic, Inc.	SYBX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	1.82	(0.92)	(1.03)	(2.26)	NA	NA	NA	8.5	15
243	Tandem Diabetes Care, Inc.	TNDM	Market Perform	Mike Kratky, CFA	Medical Devices and Technology	Dec	13.93	(1.47)	(3.18)	(1.25)	NA	NA	NA	65.2	908
244	Tango Therapeutics, Inc.@*	TNGX	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	8.05	(1.23)	(1.03)	(1.02)	NA	NA	NA	101.7	819
245	Tenet Healthcare Corporation*#	THC	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	52.40	6.84	6.03	6.23	7.7	8.7	8.4	101.6	5,321
246	Theravance Biopharma, Inc.	TBPH	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	9.95	(1.26)	(0.89)	(0.28)	NA	NA	NA	52.8	525
247	Thermo Fisher Scientific Inc.**	TMO	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	440.26	23.24	21.50	21.75	18.9	20.5	20.2	386.4	170,102
248	Theseus Pharmaceuticals, Inc.-#	THRX	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	2.11	(1.31)	(1.53)	(1.88)	NA	NA	NA	43.6	92
249	Traverse Therapeutics, Inc.	TVTX	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	5.46	(4.37)	(1.41)	(4.91)	NA	NA	NA	75.1	410
250	Trevi Therapeutics, Inc.	TRVI	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	1.30	(0.45)	(0.30)	(0.42)	NA	NA	NA	99.5	129
251	Turnstone Biologics Corp.	TSBX	Market Perform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	1.83	(1.56)	(2.27)	(2.82)	NA	NA	NA	22.8	42
252	Twist Bioscience Corporation^	TWST	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Sep	16.15	(4.03)	(3.65)	(3.15)	NA	NA	NA	57.4	927
253	Ultragenyx Pharmaceutical Inc.	RARE	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	34.38	(10.12)	(8.38)	(6.12)	NA	NA	NA	82.1	2,823
254	uniQure N.V.	QURE	Outperform	Joseph P. Schwartz	Biopharma / Rare Diseases	Dec	5.80	(2.71)	(6.40)	(3.85)	NA	NA	NA	47.8	277
255	UnitedHealth Group Incorporated^	UNH	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	539.06	22.20	24.95	27.90	24.3	21.6	19.3	936.0	504,560
256	Universal Health Services, Inc.*#	UHS	Outperform	Whit Mayo	Healthcare Providers and Managed Care	Dec	128.57	9.88	10.47	12.43	13.0	12.3	10.3	70.8	9,108
257	Vaxcyte, Inc.@*	PCVX	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	47.44	(3.44)	(3.32)	(4.26)	NA	NA	NA	95.2	4,514
258	Veracyte, Inc.	VCYT	Outperform	Puneet Souda	Life Science Tools and Diagnostics	Dec	21.50	0.00	0.13	0.13	NA	NA	NA	73.0	1,570
259	Verastem, Inc.	VSTM	Suspended Coverage		Biopharma / Immuno-Oncology	Dec	6.10	NA	NA	NA	NA	NA	NA	25.3	154
260	Vericel Corporation@*	VCEL	Outperform	Mike Kratky, CFA	Medical Devices and Technology	Dec	32.87	(0.35)	(0.13)	0.19	NA	NA	NA	47.7	1,569
261	Vertex Pharmaceuticals Incorporated+	VRTX	Outperform	David Risinger, CFA	Biopharma / Diversified Biopharmaceuticals	Dec	371.88	14.76	15.06	16.69	25.2	24.7	22.3	257.7	95,827
262	Vincorx Pharma, Inc.	VINC	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	0.88	(3.11)	(2.11)	(0.48)	NA	NA	NA	21.4	19
263	Viking Therapeutics, Inc.*##	VKTX	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	9.43	(0.90)	(0.95)	(1.23)	NA	NA	NA	100.0	943
264	Vir Biotechnology, Inc.	VIR	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease	Dec	8.53	3.89	(4.86)	(5.50)	2.2	NA	NA	134.5	1,147
265	Viracta Therapeutics, Inc.@*	VIRX	Outperform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	0.66	(1.30)	(1.21)	(1.27)	NA	NA	NA	38.6	25
266	Viridian Therapeutics, Inc.	VRDN	Outperform	Thomas J. Smith	Biopharma / Immunology & Metabolism	Dec	13.36	(4.05)	(5.06)	(4.93)	NA	NA	NA	58.5	782
267	Waters Corporation**	WAT	Market Perform	Puneet Souda	Life Science Tools and Diagnostics	Dec	250.45	12.02	11.73	12.54	20.8	21.4	20.0	59.1	14,808
268	Wave Life Sciences Ltd.@*	WVE	Market Perform	Joseph P. Schwartz	Biopharma / Genetic Medicine	Dec	4.90	(2.05)	(0.37)	(0.93)	NA	NA	NA	99.0	485
269	Werewolf Therapeutics, Inc.	HOWL	Outperform	Daina M. Graybosch, Ph.D.	Biopharma / Immuno-Oncology	Dec	2.10	(2.02)	(0.65)	0.13	NA	NA	16.2	35.7	75
270	Xencor, Inc.	XNCR	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	16.86	(0.93)	(3.14)	(4.89)	NA	NA	NA	60.9	1,026
271	Xenon Pharmaceuticals Inc.#--	XENE	Outperform	Marc Goodman	Biopharma / Neuroscience	Dec	29.41	(2.06)	(2.75)	(3.10)	NA	NA	NA	65.4	1,924
272	Xeris Biopharma Holdings, Inc.	XERS	Outperform	Roanna Ruiz, Ph.D.	Biopharma / Infectious Disease	Dec	1.66	(0.70)	(0.45)	(0.35)	NA	NA	NA	138.1	229
273	Zai Lab Ltd	ZLAB	Outperform	Jonathan Chang, Ph.D., CFA	Biopharma / Emerging Oncology	Dec	27.86	(4.63)	(3.37)	(2.34)	NA	NA	NA	988.4	27,536
274	Zentalis Pharmaceuticals, Inc@*	ZNTL	Market Perform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	9.90	(4.48)	(4.63)	(4.51)	NA	NA	NA	70.8	701
275	Zymeworks Inc.	ZYME	Market Perform	Andrew Berens, M.D.	Biopharma / Targeted Oncology	Dec	7.11	1.90	(2.31)	(0.92)	3.7	NA	NA	70.0	498



Leerink Partners Coverage List

Updated on: 11/10/2023

Company	Ticker	Rating	Analyst	Sector	Year	Closing Price (\$)	2022A (\$)	2023E (\$)	2024E (\$)	2022E	2023E	2024E	P/E	Shares Outstanding (MM)	Market Cap (\$MM)
---------	--------	--------	---------	--------	------	--------------------	------------	------------	------------	-------	-------	-------	-----	-------------------------	-------------------

Notes: GAAP presented unless noted; ^ EPS excludes 1x items & other charges; + EPS excludes stock option expense & other stock charges; ~operating EPS excludes 1x items & other charges; \* operating EPS excludes stock option expense & other charges; ^pro forma EPS excludes 1x items and other charges; \*\* EPS excludes 1 time charges & amortization of intangibles; ## EPS excludes amortization of intangibles; # EPS IFRS; +++EPS net of royalties; ---EPS excludes stock comp, transaction expenses, & purchase accounting adjustments; @@ EPS excludes changes in fair value of derivative instruments; < Pro forma non-GAAP diluted EPS; #+ EPS diluted, excludes option expense; ``EPS diluted non-GAAP, excludes option expense; ````EPS diluted non-GAAP including excluded items; ^\*EPS fully diluted, as converted; #^ EPS excludes 1x items & other charges, but includes option expense; \*# Adjusted non-GAAP EPS; \*\*^ EPS diluted, adjusted FAS123R option expense included; +\*diluted, adjusted EPS from continuing operations; ~+GAAP EPS per ADS; ~# USDEPS Fully diluted; #~ EPS-Basic; ~^~ non-GAAP EPS- Basic; @\* Diluted EPS; \*## Pro forma EPS; ~#^ Adjusted/non-GAAP EPS, ex. 1x items; \*\*\* Adj. EPS excludes amortization, stock-based comp, & other items not reflective of core operations; \*#\* Adjusted EPS includes impact of RAC release and discreet tax benefits; ^^ 2Q19 EPS adjusted for impact of IPO; ^# Core EPS per ADR; ~~#EPS estimates reflect core EPS, Excl. extraordinary items & reflects IFRS restatement, Incl. options expense.; \*#^ Adj. EBITDA; ^^\*Non-IFRS diluted EPS; ^\*~ Cash EPS

Notes: P/E calculated using prior day closing price and EPS in local currency; Source: FactSet, Company Information, Leerink Partners LLC Research estimates

# Disclosure Appendix

## Analyst Certification

Each analyst certifies that the views expressed in this report accurately reflect their views and that no part of their compensation was, is, or will be directly related to the specific recommendation or views contained in this report.

---

## Rating Distribution as of 9/30/2023

---

Coverage Universe	Count	Percent
Outperform (Buy)	211	65.1%
Market Perform (Hold/Neutral)	101	31.2%
Underperform (Sell)	12	3.7%

Rec'd Inv. Banking Serv. in Prev. 12 months	Count	Percent
Outperform (Buy)	64	30.3%
Market Perform (Hold/Neutral)	7	6.9%
Underperform (Sell)	0	0.0%

## Explanation of Ratings

**Outperform (Buy):** We expect this stock to outperform its benchmark over the next 12 months.

**Market Perform (Hold/Neutral):** We expect this stock to perform in line with its benchmark over the next 12 months.

**Underperform (Sell):** We expect this stock to underperform its benchmark over the next 12 months.

The degree of outperformance or underperformance required to warrant an Outperform or an Underperform rating should be commensurate with the risk profile of the company.

For the purposes of these definitions the relevant benchmark for "Leerink Partners" branded healthcare and life sciences equity research will be the S&P 600® Health Care Index for issuers with a market capitalization of less than \$2 billion and the S&P 500® Health Care Index for issuers with a market capitalization over \$2 billion.

## Important Disclosures

This information (including, but not limited to, prices, quotes and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice. The information is intended for Institutional Use Only and is not an offer to sell or a solicitation to buy any product to which this information relates. Leerink Partners LLC ("Firm"), its officers, directors, employees, proprietary accounts and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this report. The Firm's research analysts, salespeople, traders and other professionals may provide oral or written market commentary or trading strategies that are contrary to opinions expressed in this report. The Firm's asset management group and proprietary accounts may make investment decisions that are inconsistent with the opinions expressed in this document. The past performance of securities does not guarantee or predict future performance. Transaction strategies described herein may not be suitable for all investors. This document may not be reproduced or circulated without Leerink Partners' written authority. Additional information is available upon request by contacting the Editorial Department, Leerink Partners, 53 State Street, 40th Floor, Boston, MA 02109.

Like all Firm employees, research analysts receive compensation that is impacted by, among other factors, overall firm profitability, which includes revenues from, among other business units, Institutional Equities, Research, and Investment Banking. Research analysts, however, are not compensated for a specific investment banking services transaction. To the extent Leerink Partners research reports are referenced in this material, they are either attached hereto or information about these companies, including prices, rating, market making status, price charts, compensation disclosures, Analyst Certifications, etc. is available on <https://leerink.bluematrix.com/sellside/Disclosures.action>.

MEDACorp LLC, an affiliate of Leerink Partners, is a global network of independent healthcare professionals (Key Opinion Leaders and consultants) providing industry and market insights to Leerink Partners and its clients.

© 2023 Leerink Partners LLC. All Rights Reserved. Member FINRA/SIPC.

## Research Management

### Jim Kelly

Director of Equity Research  
(212) 277-6096  
jim.kelly@leerink.com

### Julia Belladonna

Associate Director of Research  
(212) 404-4524  
julia.belladonna@leerink.com

## Diversified Biopharmaceuticals

### David Risinger, CFA

(212) 404-4539  
david.risinger@leerink.com

### Bryan R. Dollinger, Ph.D.

(212) 404-4537  
bryan.dollinger@leerink.com

### Daniel Tarjan, Ph.D.

(617) 918-4014  
daniel.tarjan@leerink.com

## Targeted Oncology

### Andrew Berens, M.D.

(212) 277-6108  
andrew.berens@leerink.com

### Christopher Liu, Pharm.D.

(212) 277-6192  
christopher.liu@leerink.com

### Kenneth Shields

(212) 277-6190  
ken.shields@leerink.com

### Amanda Acosta-Ruiz, Ph.D.

(212) 404-4591  
amanda.acostaruz@leerink.com

### Emily Shutman

(212) 404-4599  
emily.shutman@leerink.com

## Immuno-Oncology

### Daina M. Graybosch, Ph.D.

(212) 277-6128  
daina.graybosch@leerink.com

### Rabib S. Chaudhury, Ph.D.

(212) 277-6268  
rabib.chaudhury@leerink.com

### Jeffrey La Rosa

(212) 277-6103  
jeffrey.larosa@leerink.com

## Emerging Oncology

### Jonathan Chang, Ph.D., CFA

(617) 918-4015  
jonathan.chang@leerink.com

### Faisal A. Khurshid

(617) 918-4025  
faisal.khurshid@leerink.com

### Matthew Cowper, M.D.

(617) 918-4890  
matthew.cowper@leerink.com

### Dylan J. Drakes, Ph.D.

(617) 918-4712  
dylan.drakes@leerink.com

## Genetic Medicine

### Mani Foroohar, M.D.

(212) 277-6089  
mani.foroohar@leerink.com

### Lili Nsongo, Ph.D.

(212) 277-6229  
lili.nsongo@leerink.com

### CJ Yeh, M.D.

(212) 404-4552  
christopher.yeh@leerink.com

## Immunology & Metabolism

### Thomas J. Smith

(212) 277-6069  
thomas.smith@leerink.com

### Nat Charoensook, Ph.D., CFA

(212) 277-6264  
nat.charoensook@leerink.com

### Will Humphrey

(212) 277-6255  
william.humphrey@leerink.com

## Neuroscience

### Marc Goodman

(212) 277-6137  
marc.goodman@leerink.com

### Rudy Li, Ph.D., CFA

(212) 277-6127  
rudy.li@leerink.com

### Basma Radwan, Ph.D.

(212) 277-6151  
basma.radwan@leerink.com

### Madhu Yennawar, Ph.D.

(212) 277-6220  
madhu.yennawar@leerink.com

## Rare Disease

### Joseph P. Schwartz

(617) 918-4575  
joseph.schwartz@leerink.com

### Jenny L. Gonzalez-Armenta, Ph.D.

(212) 277-6221  
jenny.gonzalezarmenta@leerink.com

### Joori Park, Ph.D.

(617) 918-4098  
joori.park@leerink.com

### Will Soghikian

(617) 918-4552  
will.soghikian@leerink.com

## Infectious Disease, Endocrine & Cardiovascular Disorders

### Roanna Ruiz, Ph.D.

(212) 277-6144  
roanna.ruiz@leerink.com

### Rosa Chen, Ph.D.

(212) 404-4522  
rosa.chen@leerink.com

### Nik Gasic, Pharm.D.

(212) 277-6147  
nik.gasic@leerink.com

## Life Science Tools & Diagnostics

### Puneet Souda

(212) 277-6091  
puneet.souda@leerink.com

### Isabella Prugue

(212) 277-6126  
isabella.prugue@leerink.com

### Philip S. Song

(212) 404-4587  
philip.song@leerink.com

### Michael Sonntag

(212) 277-6048  
michael.sonntag@leerink.com

## Medical Devices and Technology

### Mike Kratky, CFA

(212) 277-6111  
mike.kratky@leerink.com

### Brett Gasaway

(212) 404-4588  
brett.gasaway@leerink.com

## Healthcare Providers and Managed Care

### Whit Mayo

(629) 802-2560  
whit.mayo@leerink.com

### John French

(212) 277-6225  
john.french@leerink.com

### Alberta Massey

(212) 277-6263  
alberta.massey@leerink.com

### Morgan T. McCarthy

(212) 277-6224  
morgan.mccarthy@leerink.com

## Editorial

### SR. EDITOR/SUPERVISORY ANALYST

Thomas A. Marsilio  
(212) 277-6040  
thomas.marsilio@leerink.com

### SUPERVISORY ANALYSTS

Robert Egan  
bob.egan@leerink.com

Mike He  
mike.he@leerink.com

Emily Singletary  
(212) 277-6115  
emily.singletary@leerink.com

Jose Jordan  
(212) 404-7236  
jose.jordan@leerink.com